Found "Health Promotion": 1,004 results
Sort by
Last updated

Cost-effectiveness of alginic acid in combination with proton pump inhibitor for the treatment of gastroesophageal reflux disease in systemic sclerosis patients

Systemic sclerosis (SSc) patients often become refractory to proton pump inhibitors (PPI)—a standard treatment for gastroesophageal reflux disease (GERD)—and intolerant to PPI in combination with domperidone. PPI with alginic acid is an alternative treatment option, but alginic acid is costly. We

Cost-effectiveness analysis of typhoid vaccination in Lao PDR

Abstract Background Typhoid vaccination has been shown to be an effective intervention to prevent enteric fever and is under consideration for inclusion in the national immunization program in Lao PDR. Methods A cost-utility analysis was performed using an age-structured static decision tree

A Retrospective Secondary Data Analysis of Telemedicine Service Utilization (2020-2023) Among Patients Covered By The Universal Coverage Scheme in Thailand

Abstract Objective: The National Health Security Office in Thailand introduced a telemedicine program called “Telehealth/Telemedicine” in December 2020, which aimed to reimburse telemedicine services for patients with stable chronic diseases under the Universal Coverage Scheme (UCS). The current

Telemedicine Utilization in Tertiary, Specialized, and Secondary Hospitals in Thailand

Abstract Introduction: COVID-19 has accelerated the adoption of telemedicine for counseling, follow-up examination, and treatment purposes. The official guidelines in Thailand were launched to regulate or frame the protocols for healthcare professions and teams in different organizations. Obje

Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force

Highlights This report provides practical guidance for developing or updating health technology assessment (HTA) guidelines, especially in low- and middle-income countries where HTA is increasingly used as a priority setting tool for healthcare resource allocation and achieving universa

An empirical study looking at the potential impact of increasing cost-effectiveness threshold on reimbursement decisions in Thailand

Highlights Economic evidence (cost-effectiveness information) can be used to inform policy-making process in supporting the movement towards universal health coverage. Published literature has focused on methods to set a cost-effectiveness threshold (CET) which can be used to guide the cost-eff

Framework to guide the use of mathematical modelling in evidence-based policy decision-making

Abstract Introduction The COVID-19 pandemic highlighted the significance of mathematical modelling in decision-making and the limited capacity in many low-income and middle-income countries (LMICs). Thus, we studied how modelling supported policy decision-making processes in LMICs during the pand

Early health technology assessment of tongue swab for non-sputum based pulmonary tuberculosis diagnosis in Thailand

Background Sputum-based diagnostic methods for pulmonary tuberculosis (PTB) are challenging for patients who cannot produce sputum. Non-sputum-based approaches, such as tongue swab (TS), can address this gap. This study conducts an early Health Technology Assessment (HTA) of TS for PTB diagno

The way home: a scoping review of public health interventions to increase the utilization of home dialysis in chronic kidney disease patients

Abstract Background Home dialysis (HoD) remains underutilized, despite evidence showing it provides comparable mortality rates to in-center hemodialysis (ICHD) while offering advantages such as improved quality of life and lower overall costs. This scoping review comprehensively evaluates the

Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m
10 / Page